


OSA is a Serious Health Condition




Untreated OSA can impact every organ system in the body.


In up to 98% of patients with OSA, the condition is due to abnormal anatomical features of the soft tissues and/or the structures of the maxillomandibular skeleton that cause a disproportionate anatomy of the airway

OSA is a Chronic Disease that Affects over 1 Billion People Globally

Obstructive Sleep Apnea




Unobstructed Airway



Obstructed Airway

Apnea-Hypopnea Index (AHI) measures sleep apnea severity. The AHI is the sum of the number of apneas (pauses in breathing) plus the number of hypopneas (periods of shallow breathing) that occur, on average, each hour. Apneas and hypopneas, collectively called events, must last at least 10 seconds to count as an event.




The Vivos® System is designed to target craniofacial anatomical deficiencies

The first non-surgical, non-invasive and cost-effective solution


The Vivos System Offers Significant Benefits

- Average treatment is approximately 12-24 months, after which no further active intervention is required for most patients
- Oral appliances are comfortable to wear
- Safe and noninvasive
- Offers a non-surgical, non-pharmaceutical option for patients with OSA
- Treats OSA by remodeling and enhancing the soft and hard tissues constituting the human airway
- Easy to comply with treatment protocols
- Reduce or possibly eliminate the need for surgery or lifetime CPAP or mandibular advancement therapy
- Treatment applicable and effective in patients of almost all ages
- Both near term and long-term benefits (no waiting months to see improvements)



The Vivos System

Biomimetic Oral Appliance



The Vivos DNA appliance shown is registered as a Class I oral appliance for palatal expansion.

The mRNA appliance, a version of the DNA appliance is FDA cleared as a Class II appliance.

The mRNA appliance is cleared to treat mild to moderate sleep apnea, snoring and sleep disordered breathing in adults.

The Vivos System has been shown to significantly lower Apnea Hypopnea Index (AHI) scores and improve other conditions associated with Obstructive Sleep Apnea (OSA)




Hard and soft tissues of the craniofacial complex can be non-surgically remodeled and enhanced using the proprietary Vivos System devices and clinical protocols

Vivos mRNA Appliance®

Objective Measures

Objective Measures Show the Impact of The Vivos System on an Upper Human Airway

30-Year-Old Male 14 Months Treatment



Before (March 2017)

BEFORE

31.4mm²

13.2cc

Min Area:

Total Volume:


AFTER

111.6mm²

26.5cc

Min Area: Minimum Surface Area of
Airway

Total Volume: Total Volume of Airway as
measured on the scans



After (May 2018)